RxDoctor Payments Data

Jaime Fernandez, NP

Family · Binghamton, NYNPI 1487103024

Payments from drug & device makers

$3,409in general payments, 2019–2025

Across 144 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$640
  • Amgen$597
  • Novo Nordisk$589
  • GSK$273
  • Johnson & Johnson$228
  • Pfizer$215
  • plus $866 from 11 others

What the payments were for

  • Food & beverage$3,409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,409 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$21,494
Medicare patients
53
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate14$26,916
OzempicSemaglutide19$22,541
EliquisApixaban17$21,460
JardianceEmpagliflozin12$20,006
JanuviaSitagliptin Phosphate11$14,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,965
EntrestoSacubitril/Valsartan14$13,340
Breo ElliptaFluticasone/Vilanterol17$6,469
Albuterol Sulfate HfaAlbuterol Sulfate61$2,265
Metoprolol Succinate82$1,624
Atorvastatin Calcium149$1,552
Omeprazole68$974
Levothyroxine Sodium81$951
Mirtazapine13$801
Rosuvastatin Calcium97$743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$589$22,54119 claims
PfizerEliquis$215$21,46017 claims
GSKTrelegy Ellipta, Breo Ellipta$273$20,43428 claims
Boehringer IngelheimJardiance$87$20,00612 claims
MerckJanuvia$21$14,19011 claims
NovartisEntresto$115$13,34014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →